Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

Authors
Ramalingam, S
Crawford, J
Chang, A
Manegold, C
Perez-Soler, R
Douillard, J-Y
Thatcher, Nick
Barlesi, F
Owonikoko, T
Wang, Y
Pultar, P
Zhu, J
Malik, R
Giaccone, G
Summers, Yvonne J
Issue Date
2013-11

Metadata
Show full item record
Abstract
Talactoferrin alfa is an oral dendritic cell (DC)-mediated immunotherapy (DCMI). We tested whether talactoferrin was superior to placebo in advanced non-small-cell lung cancer (NSCLC).
Citation
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). 2013, 24 (11):2875-80 Ann Oncol
Journal
Annals of Oncology
URI
http://hdl.handle.net/10541/308851
DOI
10.1093/annonc/mdt371
PubMed ID
24050956
Type
Article
Language
en
ISSN
1569-8041
Collections